ROBERT MOHR: Open Payments
NPI 1750314480 · OGDEN, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,077 in 62 payments from 21 companies in 2025. Trend: 2023 $1,513 · 2024 $1,416 · 2025 $1,077
Food & beverage: $1,063Education: $14
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 20 | $288 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $90 |
| Lilly USA, LLC | 5 | $89 |
| Otsuka America Pharmaceutical, Inc. | 5 | $75 |
| PFIZER INC. | 2 | $63 |
| Novo Nordisk Inc | 4 | $62 |
| Sumitomo Pharma America, Inc. | 2 | $53 |
| Exact Sciences Corporation | 3 | $48 |
| SANOFI-AVENTIS U.S. LLC | 2 | $40 |
| Astellas Pharma US Inc | 2 | $39 |
Products named: VRAYLAR, CAPLYTA, MOUNJARO, REXULTI, GEMTESA, Cologuard Collection Kit, TZIELD, Veozah.
Industry payments across UT — which companies pay providers there.
